COVID 19-Caregivers IGg Seroconversion

Study Overview
=================
Brief Summary
-----------------
According to recent publications, the percentage of caregivers infected with COVID 19 is evaluated between 10 and 30% . This great variability is due, on the one hand to the intensity of the influx of covid plus patients and, on the other hand, to the disparity in the preparation of caregivers in the face of this emergency. Indeed, we can understand that the strict application of hygiene rules can be faulted in the face of the volume of patients, the lack of protective equipment and the lack of specific training for caregivers in this area. As a result, within healthcare teams, there are many questions that generate anxiety: will I be able to provide care properly while protecting myself from the risk of contamination? This anxiety is also present and sometimes manifests itself aggressively in the entourage or in the vicinity of caregivers, due to lack of scientific data adapted to the local ecology of the crisis. Thus, the aim of this study is to show that the risk for caregivers of being contaminated by COVID in an area dedicated to COVID positive patients is no higher than being a caregiver in a non-COVID area that he either in the adult or pediatric sector.

Official Title
-----------------
Comparison of the Proportion of Covid19 Seroconversion of Caregivers Working or Not in the COVID Sector

Conditions
-----------------
Infection, COVID-19

Intervention / Treatment
-----------------
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: caregivers staff assigned to a non-intensive care COVID service or caregivers staff assigned to a non-COVID adult service or caregivers staff assigned to a non-COVID pediatric service Age > = 18 years old With health insurance Express consent Exclusion Criteria: Protected persons Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid area<br> | Other: Blood sampling<br>* 3 blood samples (D0, D15 and D30) will be taken from each participant<br>|
| Non-Covid area<br> | Other: Blood sampling<br>* 3 blood samples (D0, D15 and D30) will be taken from each participant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Seroconversion | Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation. | Day1 | 
| Seroconversion | Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation. | Day 15 | 
| Seroconversion | Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation. | Day 30 |